Table 3.
Prognostic prediction models for the outcomes of patients with locally advanced cervical squamous cell cancer
Prediction Models | Training | Testing | ||||
---|---|---|---|---|---|---|
Wald Test | P-value | C-index | Wald Test | P-value | C-index | |
Progression-free survival | ||||||
2018 FIGO staging system | 20.83 | <0.001 | 0.657 | 10.82 | 0.001 | 0.677 |
Clinical model | 33.57 | <0.001 | 0.731 | 15.94 | <0.001 | 0.725 |
Rad-PFS | 40.17 | <0.001 | 0.764 | 13.62 | <0.001 | 0.762 |
Combined model | 50.67 | <0.001 | 0.792 | 21.28 | <0.001 | 0.809 |
Overall survival | ||||||
2018 FIGO staging system | 12.54 | <0.001 | 0.665 | 5.54 | 0.02 | 0.633 |
Clinical model | 22.53 | <0.001 | 0.708 | 5.96 | 0.01 | 0.693 |
Rad-OS | 23.97 | <0.001 | 0.793 | 12.72 | <0.001 | 0.750 |
Combined model | 31.59 | <0.001 | 0.822 | 13.43 | <0.001 | 0.785 |
PFS progression-free survival, OS overall survival, FIGO Federation of Gynecology and Obstetrics.